Superparamagnetic iron oxide (SPIO) enhanced MRI for the detection of lymph node metastasis of uterine cervical and endometrial cancer

Superparamagnetic iron oxide (SPIO) enhanced MRI for the detection of lymph node metastasis of uterine cervical and endometrial cancer - Superparamagnetic iron oxide (SPIO) enhanced MRI for the detection of lymph node metastasis of uterine cervical and endometrial cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023607

Enrollment

Registered

2017-09-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine cervical cancer uterine endometrial cancer

Interventions

SPIO (Ferucabotran) is administered by intravenous or local injection, and MRI is performed after a few hours.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Case of cervical or endometrial cancer planned lymph node dissection 2.Case which is obtained agreement of participation in this study

Exclusion criteria

Exclusion criteria: 1.pregnancy 2.metal placement or claustrophobia 3.allergy of iron or SPIO

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of lymph node metastasis	—

Secondary

Measure	Time frame
safety of administration of SPIO	—

Countries

Japan

Contacts

Public ContactKosuke Murakami

Kindai University Faculty of Medicine Department of Obstetrics & Gynecology

kmurakami@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026